Monday, March 20, 2023 Daily Archives

Critical Factors of Fill Finish Manufacturing for Large Molecules

by

With the explosion of the large molecule (biologics) market, the industry has entered a new era of drug development. This growth — 10% to 15% each year — is being driven by monoclonal antibodies (mAbs), which are anticipated to have worldwide sales of over $240 billion by 2025. However, with this expanding market comes some considerable challenges for drug manufacturers due to the fragile nature and instability of these large, complex molecules. As compared to small molecules, large molecules generally…

March 20, 2023

Big Pharma: Biotech partnering will shine amid financial downturn

by

The difficult financial landscape may have dampened biopharma M&A but biotech partnering remains robust and crucial to bring innovation to industry, say Roche and Novartis. The last two years saw some of the lowest levels of M&A in the pharma space since the 2008 financial crash. Meanwhile, the industry has seen private funding dry up, and further problems are on the horizon following the recent Silicon Valley Bank (SVB) collapse and the ongoing crisis at Credit Suisse. “It’s been a…

March 20, 2023

Great Ormond Street Hospital and Leucid ink CAR-T manufacturing deal

by

Great Ormond Street Hospital (GOSH) has agreed to manufacture Leucid Bio’s lead asset, LEU011 at the Zayed Center for Research in London, UK. Leucid, a UK clinical stage biotech firm, which is focused on developing chimeric antigen receptor T-cell (CAR-T) therapies using its lateral CAR platform to treat refractory cancers, has collaborated with GOSH to manufacture LEU011, a lateral CAR targeting NKG2D ligands, for use in human clinical studies. “We decided to partner with GOSH to manufacture our CAR T-cell…

March 20, 2023

Regeneron probing bispecific Abs with eye on future cancer therapies

by

Bispecific antibodies that mirror the natural biology of immune T-cells are the key to a new generation of cancer therapies, according to Regeneron.  Antibodies bind specific antigens – molecular targets such as proteins expressed on the surface of tumors. Bispecific antibodies, as the name suggests, can bind two antigens at the same time. This binding ability means they have significant potential as therapies according to Eric Smith, senior director of bispecific antibodies at Regeneron, who shared details of the firm’s…

March 20, 2023